Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-23b/27b cluster in bladder cancer

International Journal of Oncology

Volumn 46, Issue 2, 2015, Pages 487-496

  Chiyomaru, Takeshi ^a   Seki, Naohiko ^b   Inoguchi, Satoru ^a   Ishihara, Tomoaki ^a   Mataki, Hiroko ^a   Matsushita, Ryosuke ^a   Goto, Yusuke ^b   Nishikawa, Rika ^b   Tatarano, Shuichi ^a   Itesako, Toshihiko ^a   Nakagawa, Masayuki ^a   Enokida, Hideki ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder cancer; C Met; EGFR; Microrna; MiR 23b; MiR 27b; Tumor suppressor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 23B; MICRORNA 27B; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; MIRN23 MICRORNA, HUMAN; MIRN27 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; COMPUTER MODEL; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING; BIOSYNTHESIS; BLADDER TUMOR; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOGENESIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84918520113     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2752     Document Type: Article

References (48)

1. S iegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. L uke C, Tracey E, Stapleton A and Roder D: Exploring contrary trends in bladder cancer incidence, mortality and survival: implications for research and cancer control. Intern Med J 40: 357-362, 2010.
3. Zuiverloon TC, Nieuweboer AJ, Vekony H, Kirkels WJ, Bangma CH and Zwarthoff EC: Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 61: 128-145, 2012.
4. M attick JS: RNA regulation: a new genetics? Nat Rev Genet 5: 316-323, 2004.
5. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
6. E squela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
7. Itesako T, Seki N, Yoshino H, et al: The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. PLoS One 9: e84311, 2014.
8. Fuse M, Kojima S, Enokida H, et al: Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. J Hum Genet 57: 691-699, 2012.
9. Hidaka H, Seki N, Yoshino H, et al: Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget 3: 44-57, 2012.
10. Nohata N, Hanazawa T, Kikkawa N, et al: Tumour suppressive microRNA-874 regulates novel cancer networks in maxillary sinus squamous cell carcinoma. Br J Cancer 105: 833-841, 2011.
11. Ichimi T, Enokida H, Okuno Y, et al: Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 125: 345-352, 2009.
12. Y oshino H, Chiyomaru T, Enokida H, et al: The tumoursuppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 104: 808-818, 2011.
13. Nishikawa R , G oto Y, Kojima S, et al: Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. Int J Oncol 45: 401-410, 2014.
14. K ojima S, Enokida H, Yoshino H, et al: The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM 1 in prostate cancer. J Hum Genet 59: 78-87, 2014.
15. K inoshita T, Nohata N, Hanazawa T, et al: Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma. Br J Cancer 109: 2636-2645, 2013.
16. Y oshino H, Enokida H, Itesako T, et al: Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in renal cell carcinoma. Cancer Sci 104: 1567-1574, 2013.
17. Y amasaki T, Yoshino H, Enokida H, et al: Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA- 133a in bladder cancer. Int J Oncol 40: 1821-1830, 2012.
18. Nohata N, Hanazawa T, Enokida H and Seki N: microRNA- 1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget 3: 9-21, 2012.
19. K ojima S, Chiyomaru T, Kawakami K, et al: Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 106: 405-413, 2012.
20. K awakami K, Enokida H, Chiyomaru T, et al: The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer 48: 827-836, 2012.
21. Nohata N, Hanazawa T, Kikkawa N, et al: Identification of novel molecular targets regulated by tumor suppressive miR-1/ miR-133a in maxillary sinus squamous cell carcinoma. Int J Oncol 39: 1099-1107, 2011.
22. Jin L, Wessely O, Marcusson EG, Ivan C, Calin GA and Alahari SK : Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-alpha in breast cancer. Cancer Res 73: 2884-2896, 2013.
23. Chiyomaru T, Enokida H, Tatarano S, et al: miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102: 883-891, 2010.
24. Ishteiwy RA, Ward TM, Dykxhoorn DM and Burnstein KL : The microRNA-23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. PLoS One 7: e52106, 2012.
25. Husted S, Sokilde R, Rask L, et al: MicroRNA expression profiles associated with development of drug resistance in Ehrlich ascites tumor cells. Mol Pharm 8: 2055-2062, 2011.
26. Park YT, Jeong JY, Lee MJ, et al: MicroRNAs overexpressed in ovarian ALD H1-positive cells are associated with chemoresistance. J Ovarian Res 6: 18, 2013.
27. Inoguchi S, Seki N, Chiyomaru T, et al: Tumour-suppressive microRNA-24-1 inhibits cancer cell proliferation through targeting FOXM1 in bladder cancer. FEBS Lett 588: 3170-3179, 2014.
28. S haw AT, Hsu PP, Awad MM and Engelman JA: Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 13: 772-787, 2013.
29. Herbst RS: Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59: 21-26, 2004.
30. Oda K, Matsuoka Y, Funahashi A and Kitano H: A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 1: 2005.0010, 2005.
31. Chow NH, Liu HS, Lee EI, et al: Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 17: 1293-1296, 1997.
32. M ellon K, Wright C, Kelly P, Horne CH and Neal DE : Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 153: 919-925, 1995.
33. Bue P, Wester K, Sjostrom A, et al: Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer 76: 189-193, 1998.
34. O'Brien LE , Tang K, Kats ES , Schutz-Geschwender A, Lipschutz JH and Mostov KE : ERK and MM Ps sequentially regulate distinct stages of epithelial tubule development. Dev Cell 7: 21-32, 2004.
35. Graziani A, Gramaglia D, Cantley LC and Comoglio PM: The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem 266: 22087-22090, 1991.
36. Boccaccio C, Ando M, Tamagnone L, et al: Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391: 285-288, 1998.
37. M onga SP, Mars WM, Pediaditakis P, et al: Hepatocyte growth factor induces Wnt-independent nuclear translocation of betacatenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res 62: 2064-2071, 2002.
38. Cheng HL, Trink B, Tzai TS, et al: Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol 20: 1544-1550, 2002.
39. M iyata Y, Sagara Y, Kanda S, Hayashi T and Kanetake H: Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol 40: 496-504, 2009.
40. E ngelman JA, Zejnullahu K, Mitsudomi T, et al: ME T amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
41. Goldman JW, Laux I, Chai F, et al: Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymalepithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 118: 5903-5911, 2012.
42. K efas B, Godlewski J, Comeau L, et al: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572, 2008.
43. L i Y, Vandenboom TG II, Wang Z, et al: miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 70: 1486-1495, 2010.
44. Chiyomaru T, Yamamura S, Fukuhara S, et al: Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer. PLoS One 8: e58929, 2013.
45. Acunzo M, Visone R, Romano G, et al: miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 31: 634-642, 2012.
46. Y an D, Dong Xda E, Chen X, et al: MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem 284: 29596-29604, 2009.
47. Taulli R, Bersani F, Foglizzo V, et al: The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 119: 2366-2378, 2009.
48. Acunzo M, Romano G, Palmieri D, et al: Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci US A 110: 8573-8578, 2013.